Hackensack Meridian Health said it will host two Pfizer trial sites for the BEETHOVEN study of an investigational C. diff vaccine.

Hackensack Meridian Health says it will host two Pfizer sites for a phase 3 clinical trial of an investigational vaccine against C. difficile infection, also known as C. diff.

The health network said the BEETHOVEN study is designed for adults 65 years of age or older. The trial is described as placebo-controlled, double-blind and randomized.

ClinicalTrials.gov lists Pfizer as the sponsor of the study, and other trial-site pages also identify BEETHOVEN as a Pfizer-sponsored C. diff vaccine trial.

Study details

  • Trial name: BEETHOVEN
  • Sponsor: Pfizer
  • Population: adults 65 and older
  • Type: phase 3 C. diff vaccine study

Revision note

Initial automated publication.